Tech Company Financing Transactions
Antag Therapeutics Funding Round
Antag Therapeutics closed a $84.6 million Series A financing round on 12/4/2024. Investors included Versant Ventures, Dawn Biopharma and EIFO.
Transaction Overview
Company Name
Announced On
12/4/2024
Transaction Type
Venture Equity
Amount
$84,600,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to support the clinical development of AT-7687, a novel, once-weekly subcutaneous antagonist of the Glucose-Dependent Insulinotropic Polypeptide Receptor (GIPR) and to accelerate the expansion of its pipeline of monthly injectable therapies.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
COBIS Ole Maaløes Vej 3
Copenhagen, 2200
Denmark
Copenhagen, 2200
Denmark
Phone
Undisclosed
Website
Email Address
Overview
Antag Therapeutics is a biotechnology company dedicated to developing innovative peptide-based therapies to address obesity and related cardiometabolic disorders. Our approach is rooted in decades of pioneering research from the University of Copenhagen, with a focus on the complexities of incretin physiology.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Alexander Sparre-Ulrich
Chief Financial Officer
Jakob Hansen
Chief Medical Officer
Richard Nkulikiyinka
Chief Scientific Officer
Mads Christensen
Vice President
Ingrid Bøgh
VP - Operations
John Boland
VP - Regulatory Affairs
Sandra Cottrell
Browse more venture capital transactions:
Prev: 12/4/2024: Briefcase venture capital transaction
Next: 12/4/2024: Saltbox Mgmt venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on all VC transactions involving tech companies. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs